FORWARD-LOOKING DISCLAIMER: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section.
Executive Summary
Revenue (2025)
$45.9B
+10% CER
EBITDA Margin
41.3%
-4.4 pp
Net Income
$15.2B
+1.5%
Employees
72,000
+18%
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become the global leader in diabetes care and a dominant player in obesity and rare disease markets.
Key Market Positions:
30.1% global diabetes value market share
45.8% GLP-1 diabetes value market share
59.6% branded GLP-1 obesity volume share
~50% of global insulin market
2026 Outlook:Guidance shows 5-13% decline at CER — first projected annual contraction since 2017, driven by US pricing pressures and intensified competition from Eli Lilly.
Revenue Mix by Segment (2025)
Revenue Growth (DKK Billions)
1. Company History
Key Milestones
Year
Event
1923
Nordisk Insulinlaboratorium founded by August Krogh and Hans Christian Hagedorn
1925
Novo Terapeutisk Laboratorium founded by Harald and Thorvald Pedersen
1936
NPH insulin developed (first longer-acting insulin)
1982
First recombinant human insulin produced
1985
NovoPen insulin pen launched
1989
Novo and Nordisk merge to form Novo Nordisk A/S
2010
Victoza (liraglutide) launched
2017
Ozempic (semaglutide) launched for diabetes
2021
Wegovy (semaglutide 2.4mg) launched for obesity
2022
Forma Therapeutics ($1.1B) and Dicerna ($3.3B) acquisitions
2024
Catalent fill-finish sites acquired ($11B)
2025
Akero Therapeutics acquired ($4.7B); Mike Doustdar becomes CEO
CEO Transitions
Period
CEO
Tenure
1989-2000
Mads Øvlisen
11 years
2000-2017
Lars Rebien Sørensen
17 years
2017-2025
Lars Fruergaard Jørgensen
8 years
2025-Present
Maziar "Mike" Doustdar
Current
2. Ownership Structure
Share Structure
Share Class
Shares Outstanding
Votes per DKK 0.01
Total Voting Power
A Shares (restricted)
1,074,872,000
1,000
~76%
B Shares (tradeable)
3,390,128,000
1
~24%
Major Shareholders
Shareholder
Type
Ownership
Voting Power
Novo Holdings A/S (via Foundation)
Strategic
100% A + B shares
~77%
BlackRock, Inc.
Institutional
4.07%
N/A
The Vanguard Group
Institutional
3.25%
N/A
Other Institutions
Institutional
~48%
N/A
3. Leadership / C-Suite
Name
Title
Start Date
Background
Maziar "Mike" Doustdar
President & CEO
Aug 2025
33+ years at Novo; first non-Danish CEO
Karsten Munk Knudsen
CFO
2019
MSc Economics; joined 1999
Martin Holst Lange
EVP R&D & CSO
2021 (EVP)
MD/PhD Endocrinology; joined 2002
Dave Moore
EVP US Operations
2023
30 years pharma; MBA Lehigh
Emil Kongshøj Larsen
EVP International Operations
Aug 2025
MA Political Science; joined 2007
Ludovic Helfgott
EVP Product & Portfolio Strategy
Apr 2025
MBA INSEAD; ex-AstraZeneca, McKinsey
Kasper Bødker Mejlvang
EVP CMC & Product Supply
Jan 2026
MSc Management; MBA IMD; joined 2002
4. Drug Portfolio
Diabetes Care Products
Product
Revenue (2025)
Growth (CER)
Patent Status
Peak Sales
Ozempic
$18.8B
+10%
US: 2031-32
$25B+
Rybelsus
Incl. in GLP-1
+15%
US: 2031-32
$8-10B
Victoza
~$0.8B
-36%
Generic Dec 2023
Declining
Tresiba
~$1.5B
+10%
US: 2028-29
$2B
Awiqli
Pre-launch
-
FDA resubmit Sept 2025
$3-5B
Obesity Care Products
Product
Revenue (2025)
Growth (CER)
Patent Status
Peak Sales
Wegovy (injectable)
$11.7B
+31%
US: 2031-32
$15-20B
Wegovy (oral)
Jan 2026 launch
New
US: Similar
$5-10B
Saxenda
Incl. in obesity
Declining
Generic 2025+
Declining
Rare Disease Products
Product
Revenue (2025)
Growth (CER)
Patent Status
Peak Sales
NovoSeven
~$1B
-5%
Biosimilar competition
Legacy
Alhemo (concizumab)
Growing
+50%+
New (FDA Jul 2025)
$1-2B
Norditropin
~$0.7B
+24%
Biosimilar pressure
$1-2B
Sogroya
Growing
+40%+
US: 2030s
$2B+
5. Top 5 CEO Focus Drugs
Ozempic: $18.8B revenue; foundation of diabetes franchise; CV/renal benefits
CagriSema: Phase 3 complete; FDA submission Dec 2025; 22.7% weight loss
Mim8: FDA BLA Oct 2025; superior bleed reduction in hemophilia A
Amycretin: Phase 3 Q1 2026; 24.3% weight loss in Phase 1/2; next-gen candidate
7. R&D Pipeline
Phase 3 Programs
Candidate
Indication
Expected Readout
Notes
CagriSema
Obesity, T2D
Filed Dec 2025
Amylin + GLP-1 combo
Mim8 (denecimig)
Hemophilia A
FDA late 2026
Bispecific antibody
Amycretin
Obesity, T2D
2027-28
GLP-1/amylin co-agonist
Efruxifermin
MASH (F2-F4)
2027+
FGF21 analog (Akero)
Ziltivekimab
CV inflammation
ZEUS ongoing
IL-6 inhibitor
Etavopivat
Sickle cell disease
2026+
Pyruvate kinase activator
8. Top Geographies
Region
Revenue
Share
Growth (CER)
United States
~$26.7B
58%
+8%
Europe & Canada
~$9.2B
20%
+10%
China
~$2.8B
6%
+5%
Other Emerging Markets
~$4.6B
10%
+15%
Other
~$2.5B
6%
+5%
9. Competitive Landscape
GLP-1 / Obesity Market
Company
Key Products
2025 Revenue
Position
Novo Nordisk
Ozempic, Wegovy
~$35B
Leader (losing share)
Eli Lilly
Mounjaro, Zepbound
~$30B+
Fastest growing
Amgen
MariTide (pipeline)
-
Emerging
Viking
VK2735 (pipeline)
-
Phase 3
Key Competitive Dynamic: Eli Lilly's tirzepatide achieved 25.5% weight loss vs. CagriSema's 20.2% in head-to-head trial (Feb 2026), causing 15% Novo stock drop.
10. Risks and Challenges
Risk
Severity
Impact
Competition (Lilly tirzepatide)
High
Market share erosion; trial losses
US Pricing Pressure
High
Primary driver of 2026 decline guidance
Patent Cliffs (~2031)
Medium
5-6 years to biosimilar entry
Manufacturing Capacity
Medium
FDA CRL for Awiqli; supply limits
Pipeline Execution
Medium
CagriSema underperformance
Leadership Transition
Low
New CEO; board turnover
11. Outlook and Valuation
2026 Guidance
Metric
2026 Guidance (CER)
vs. 2025
Sales Growth
-5% to -13%
Down from +10%
Operating Profit Growth
-5% to -13%
Down from +6%
Peer Comparison
Company
Market Cap
2025 Revenue
Forward P/E
Novo Nordisk
~$380B
$46B
~22x
Eli Lilly
~$750B
$48B
~35x
AstraZeneca
~$220B
$52B
~17x
Merck
~$260B
$62B
~15x
12. Patent/Exclusivity Summary
Product
Indication
US Exclusivity
EU Exclusivity
Key Risk
Ozempic
T2D
2031-32
2031
Biosimilar development
Wegovy
Obesity
2031-32
2031
Tirzepatide competition
Rybelsus
T2D (oral)
2031-32
2031
Oral competition
Victoza
T2D
Generic Dec 2023
2024+
Eroding
Tresiba
Diabetes
2028-29
Similar
Pricing pressure
Ada Patient Finder Analysis
Top Opportunities by Fit Score
Drug
Score
Per-Patient Revenue
Underdiagnosis
Ada Potential
Efruxifermin (MASH)
9/10
~$40K
>95%
Very High
Wegovy (Obesity)
7/10
~$8K
40-80%
High
Norditropin (GHD)
7/10
~$20K
90%+ (adults)
High
Mim8 (Hemophilia A)
6/10
~$200K
<10% (US)
Moderate
Ozempic (T2D)
5/10
~$6K
23%
Moderate
High-Priority Drug Deep Dives
1. Efruxifermin (MASH) - Fit Score: 9/10
Addressable Patient Funnel:
MASLD/NAFLD prevalence (US): 80-100 million (30-40% of adults)
MASH prevalence (US): 15-20 million
MASH with significant fibrosis (F2+): 5-8 million
Currently diagnosed: <5%
PITCH HOOK - Efruxifermin:
"Metabolic dysfunction-associated steatohepatitis (MASH) affects up to 20 million Americans, yet fewer than 5% are diagnosed—most discovered only when cirrhosis develops (Hepatology, 2024). Ada's comprehensive assessment of metabolic syndrome components, combined with liver-specific symptom queries, can identify high-risk patients years before hepatic decompensation. With efruxifermin pricing expected at $50,000+ annually for fibrotic MASH, early identification represents both clinical urgency and substantial commercial opportunity."
2. Wegovy (Obesity) - Fit Score: 7/10
Addressable Patient Funnel:
Obesity prevalence (US, BMI ≥30): 115 million adults (42%)
Obesity undiagnosed/undocumented: 40-80%
Eligible for Wegovy: ~80 million
Currently on anti-obesity meds: ~8 million
Addressable by Ada: 70+ million
PITCH HOOK - Wegovy:
"More than half of obese patients in primary care settings remain undiagnosed, with physicians documenting obesity in only 51% of cases (J Gen Intern Med, 2014). Ada's symptom assessment can identify obesity-related comorbidities like sleep apnea, joint pain, and metabolic indicators, prompting the crucial diagnostic conversation that 49% of patients never receive. With 70+ million eligible but untreated Americans, each patient identified represents $8,000+ in annual Wegovy revenue."
3. Norditropin/Sogroya (Growth Hormone) - Fit Score: 7/10
Addressable Patient Funnel:
Adult GHD prevalence (US): ~50,000
Adult GHD receiving treatment: <10%
Symptoms mimic normal aging: fatigue, central adiposity, reduced muscle
PITCH HOOK - Growth Hormone:
"Adult growth hormone deficiency affects approximately 50,000 Americans, yet fewer than 10% receive treatment—largely because symptoms like fatigue, central adiposity, and reduced muscle mass mimic normal aging (J Clin Endocrinol Metab, 2024). Ada's comprehensive symptom assessment can identify the cardinal symptom clusters of adult GHD, particularly in patients with pituitary history, enabling Norditropin/Sogroya conversion from the 90%+ untreated patient population."